01—Abstract
Summary
Summary of the 10-K filed February 18, 2025. Cited figures are marked; the original filing is the authoritative source.
West Pharmaceutical Services, Inc. reported consolidated net sales of $2,893.2 milliona in 2024, down from $2,949.8 million in 2023, with the decline driven mainly by the Proprietary Products segment, where net sales fell $62.8 million, or 2.6%, to $2,334.5 million.
Consolidated operating profit decreased 15.7% to $569.9 millionb, and gross profit fell 11.6% to $998.5 million as gross margin compressed to 34.5% from 38.3%. Management attributed the Proprietary Products decline to lower plant absorption from reduced customer demand, a shift in product mix, and roughly $47 million in customer incentives earned on 2024 volumes, partially offset by higher sales prices. Net income was $492.7 million, or $6.69 diluted EPS, versus $593.4 million and $7.88 in 2023.
Cash flow from operations declined to $653.4 millionc from $776.5 million, while capital expenditures rose to $377.0 million from $362.0 million to add manufacturing capacity. Cash and cash equivalents fell to $484.6 million from $853.9 million, reflecting $560.9 million of share repurchases and $59.1 million of dividend payments. Total debt was essentially flat at $202.6 million, and the company had $497.6 million of available capacity under its multi-currency revolving credit facility at year end.
The company reported that it was in compliance with all debt covenants and that it believes its liquidity is adequate for foreseeable needs. The filing shows sales outside the U.S. at 57.5% of 2024 net sales, and one customer accounted for 12.3% or $356.4 milliond of consolidated net sales. Management reported effective internal control over financial reporting as of December 31, 2024, and PricewaterhouseCoopers LLP issued an unqualified opinion on both the financial statements and internal controls.
02—Key points
Key Highlights
- Consolidated net sales were $2,893.2 million, down 1.9% from $2,949.8 million in 2023, with the Proprietary Products segment down 2.6% and Contract-Manufactured Products up 1.1%.
- Consolidated operating profit fell 15.7% to $569.9 million, and operating margin declined to 19.7% from 22.9%.
- Gross margin compressed to 34.5% from 38.3%, with Proprietary Products gross margin down to 38.6% from 43.1% on lower plant absorption and unfavorable product mix.
- Net income was $492.7 million, or $6.69 per diluted share, compared with $593.4 million, or $7.88 per diluted share, in 2023.
- Operating cash flow decreased to $653.4 million from $776.5 million, while capital expenditures increased to $377.0 million.
- The company repurchased 1,583,032 shares for $560.9 million in 2024, and cash and cash equivalents declined to $484.6 million from $853.9 million.
- One customer represented 12.3% of consolidated net sales ($356.4 million), and sales outside the U.S. were 57.5% of 2024 net sales.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2024, West Pharmaceutical Services kept $0.17.
- Revenue$2.89B100.0%
- Cost of revenue−$1.89B65.5%
- Gross profit$998.5M34.5%
- Operating costs−$428.6M14.8%
- Operating income$569.9M19.7%
- Interest, other & tax−$77.2M2.7%
- Net income$492.7M17.0%
Where FY2024 revenue went
$2.89B- Cost of revenue: $1.89B, 65% of revenue
- Net income: $492.7M, 17% of revenue
- R&D: $69.1M, 2.4% of revenue
- SG&A: $338.5M, 12% of revenue
- Other operating costs: $21.0M, 0.7% of revenue
- Interest, other & tax: $77.2M, 2.7% of revenue
Kept 17% as net incomeR&D $69.1M · 2.4%Other operating costs $21.0M · 0.7%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2024filed February 18, 2025Financial Statements
FY2024 against FY2023
| Line item | FY2024FY2023 | Change |
|---|---|---|
| Revenue | $2.89B$2.95B | −1.9% |
| Cost of Revenue | $1.89B$1.82B | +4.1% |
| Gross Profit | $998.50M$1.13B | −11.6% |
| R&D Expenses | $69.10M$68.40M | +1.0% |
| SG&A Expenses | $338.50M$353.40M | −4.2% |
| Operating Income | $569.90M$676.00M | −15.7% |
| Interest Expense | $16.20M$9.00M | +80.0% |
| Net Income | $492.70M$593.40M | −17.0% |
| EPS (Basic) | $6.75$7.98 | −15.4% |
| EPS (Diluted) | $6.69$7.88 | −15.1% |
| Shares Outstanding (Basic) | 73.00M74.30M | −1.7% |
| Shares Outstanding (Diluted) | 73.70M75.30M | −2.1% |
05—Questions
Frequently Asked Questions
Why did West's profitability decline in 2024?
Management attributed the decline mainly to lower sales volume and plant absorption in the Proprietary Products segment, as well as a less favorable product mix shifting from HVP Components to HVP Delivery Devices. Approximately $47 million in customer incentives earned on 2024 volumes also weighed on results, partially offset by higher sales prices.
How much did West return to shareholders in 2024?
West repurchased 1,583,032 shares under its share repurchase program for $560.9 million, and paid $59.1 million in dividend payments. The quarterly dividend was $0.20 per share in the first three quarters of 2024 and $0.21 in the fourth quarter.
How concentrated is West's customer base?
The ten largest customers accounted for 43.4% of consolidated net sales in 2024. One customer individually accounted for 12.3%, or $356.4 million, of consolidated net sales, contributing to both the Proprietary and Contract-Manufactured Products segments.
Is West's debt and liquidity position under pressure?
Total debt was $202.6 million at December 31, 2024, nearly unchanged from $206.8 million a year earlier. The company had no outstanding borrowings under its $500.0 million revolving credit facility, leaving $497.6 million of borrowing capacity, and it stated that it was in compliance with all debt covenants.
What is West doing to expand capacity?
Capital expenditures rose to $377.0 million in 2024 from $362.0 million in 2023, primarily for additional manufacturing capacity to meet future customer demand. Construction in progress totaled $410.8 million at year end.
06—Continue